SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Kite Pharma, Inc. to Gilead Sciences, Inc. is Fair to Shareholders

The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Kite Pharma, Inc. ("Kite Pharma" or the "Company") (NASDAQ:KITE) stock prior to August 28, 2017.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Kite Pharma, Inc. to Gilead Sciences, Inc. (NASDAQ: GILD). The transaction is valued at approximately $11.9 billion. Under the terms of the transaction, shareholders of Kite Pharma will receive $180.00 in cash for each share of Kite Pharma common stock they own. To learn more about the action and your rights, go to:

http://www.zlkdocs.com/IXYS-Info-Request-Form-ma-6064

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170829005843/en/